Advanced search
Publication Cover
Scandinavian Journal of Primary Health Care Volume 40, 2022 - Issue 1
Submit an article Journal homepage
1,088
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

General practitioners’ reflections on using PSA for diagnosis of prostate cancer. A qualitative study

Olav ThorsenThe General Practice and Care Coordination Research Group, Stavanger University Hospital, Stavanger, NorwayCorrespondence[email protected]
,
Eirik VisteThe General Practice and Care Coordination Research Group, Stavanger University Hospital, Stavanger, Norway
,
Torgeir Gilje LidThe General Practice and Care Coordination Research Group, Stavanger University Hospital, Stavanger, Norway
&
Svein R. KjosavikThe General Practice and Care Coordination Research Group, Stavanger University Hospital, Stavanger, Norway
Pages 123-128 | Received 09 Jun 2021, Accepted 29 Nov 2021, Published online: 12 Apr 2022

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  • Breidablik HJ, Meland E, Aakre KM, et al. PSA measurement and prostate cancer-overdiagnosis and overtreatment? Tidsskr nor Laegeforen. 2013;133(16):1711–1716.
  • Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive services task force. Ann Intern Med. 2011;155(11):762–771.
  • Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035.
  • Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–262.
  • Rowe TA, Brown T, Lee JY, et al. Clinician-level variation in three measures representing overuse based on the American Geriatrics society choosing wisely statement. J Gen Intern Med. 2020;35(6):1797–1802.
  • Evans R, Edwards AG, Elwyn G, et al. It's a maybe test": men's experiences of prostate specific antigen testing in primary care. Br J Gen Pract. 2007;57(537):303–310.
  • Hodgson F, Obertova Z, Brown C, et al. PSA testing in general practice. J Prim Health Care. 2012;4(3):199–204.
  • Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.
  • Loeb S, Catalona WJ. What to do with an abnormal PSA test. Oncologist. 2008;13(3):299–305.
  • Rai T, Clements A, Bukach C, et al. What influences men's decision to have a prostate-specific antigen test? A qualitative study. Fam Pract. 2007;24(4):365–371.
  • Zaat JO, van Eijk JT. General practitioners' uncertainty, risk preference, and use of laboratory tests. Med Care. 1992;30(9):846–854.
  • Viste E, Vinje CA, Lid TG, et al. Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system – the Stavanger experience. Scand J Prim Health Care. 2020;38(3):315–322.
  • Malterud K. Systematic text condensation: a strategy for qualitative analysis. Scand J Public Health. 2012;40(8):795–805.
  • Malterud K. Theory and interpretation in qualitative studies from general practice: why and how? Scand J Public Health. 2016;44(2):120–129.
  • Pickles K, Carter SM, Rychetnik L, et al. General practitioners' experiences of, and responses to, uncertainty in prostate cancer screening: insights from a qualitative study. PLOS One. 2016;11(4):e0153299.
  • Pickles K, Carter SM, Rychetnik L, et al. Doctors' perspectives on PSA testing illuminate established differences in prostate cancer screening rates between Australia and the UK: a qualitative study. BMJ Open. 2016;6(12):e011932.
  • Moss S, Melia J, Sutton J, et al. Prostate-specific antigen testing rates and referral patterns from general practice data in England. Int J Clin Pract. 2016;70(4):312–318.
  • Ross LE, Hall IJ, Howard DL, et al. Primary care physicians beliefs about prostate-specific antigen evidence uncertainty, screening efficacy, and test use. J Natl Med Assoc. 2018;110(5):491–500.
  • Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the us preventive services task force. JAMA. 2018;319(18):1914–1931.
  • Tikkinen KAO, Dahm P, Lytvyn L, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline. BMJ. 2018;362:k3581.
  • Charvin M, Launoy G, Berchi C. The effect of information on prostate cancer screening decision process: a discrete choice experiment. BMC Health Serv Res. 2020;20(1):467.
  • Clift AK, Coupland CA, Hippisley-Cox J. Prostate-specific antigen testing and opportunistic prostate cancer screening: a cohort study in England, 1998-2017. Br J Gen Pract. 2021;71(703):e157–e65.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.